Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability.
Disability
Pouch
Ulcerative Colitis
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
06
01
2021
revised:
25
04
2021
accepted:
17
05
2021
pubmed:
26
5
2021
medline:
17
3
2022
entrez:
25
5
2021
Statut:
ppublish
Résumé
Disability in patients with medically refractory ulcerative colitis (UC) after total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is not well understood. The aim of this study was to compare disability in patients with IPAA vs medically managed UC, and identify predictors of disability. This was a multicenter cross-sectional study performed at 5 academic institutions in New York City. Patients with medically or surgically treated UC were recruited. Clinical and socioeconomic data were collected, and the Inflammatory Bowel Disease Disability Index (IBD-DI) was administered to eligible patients. Predictors of moderate-severe disability (IBD-DI ≥35) were assessed in univariable and multivariable models. A total of 94 patients with IPAA and 128 patients with medically managed UC completed the IBD-DI. Among patients with IPAA and UC, 35 (37.2%) and 30 (23.4%) had moderate-severe disability, respectively. Patients with IPAA had significantly greater IBD-DI scores compared with patients with medically managed UC (29.8 vs 17.9; P < .001). When stratified by disease activity, patients with active IPAA disease had significantly greater median IBD-DI scores compared with patients with active UC (44.2 vs 30.4; P = .01), and patients with inactive IPAA disease had significantly greater median IBD-DI scores compared with patients with inactive UC (23.1 vs 12.5; P < .001). Moderate-severe disability in patients with IPAA was associated with female sex, active disease, and public insurance. Patients with IPAA have higher disability scores than patients with UC, even after adjustment for disease activity. Female sex and public insurance are predictive of significant disability in patients with IPAA.
Sections du résumé
BACKGROUND & AIMS
Disability in patients with medically refractory ulcerative colitis (UC) after total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is not well understood. The aim of this study was to compare disability in patients with IPAA vs medically managed UC, and identify predictors of disability.
METHODS
This was a multicenter cross-sectional study performed at 5 academic institutions in New York City. Patients with medically or surgically treated UC were recruited. Clinical and socioeconomic data were collected, and the Inflammatory Bowel Disease Disability Index (IBD-DI) was administered to eligible patients. Predictors of moderate-severe disability (IBD-DI ≥35) were assessed in univariable and multivariable models.
RESULTS
A total of 94 patients with IPAA and 128 patients with medically managed UC completed the IBD-DI. Among patients with IPAA and UC, 35 (37.2%) and 30 (23.4%) had moderate-severe disability, respectively. Patients with IPAA had significantly greater IBD-DI scores compared with patients with medically managed UC (29.8 vs 17.9; P < .001). When stratified by disease activity, patients with active IPAA disease had significantly greater median IBD-DI scores compared with patients with active UC (44.2 vs 30.4; P = .01), and patients with inactive IPAA disease had significantly greater median IBD-DI scores compared with patients with inactive UC (23.1 vs 12.5; P < .001). Moderate-severe disability in patients with IPAA was associated with female sex, active disease, and public insurance.
CONCLUSIONS
Patients with IPAA have higher disability scores than patients with UC, even after adjustment for disease activity. Female sex and public insurance are predictive of significant disability in patients with IPAA.
Identifiants
pubmed: 34033922
pii: S1542-3565(21)00571-1
doi: 10.1016/j.cgh.2021.05.033
pmc: PMC9638721
mid: NIHMS1707586
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e761-e769Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK111995
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Références
Gut. 2013 Mar;62(3):368-75
pubmed: 22717453
Aliment Pharmacol Ther. 2018 Jan;47(1):6-15
pubmed: 28994131
Gastroenterology. 2021 Apr;160(5):1452-1460.e21
pubmed: 33421515
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1377-1386.e5
pubmed: 32526341
J Crohns Colitis. 2016 Dec;10(12):1378-1384
pubmed: 27282401
Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3
pubmed: 28625817
Am J Gastroenterol. 2019 Feb;114(2):276-290
pubmed: 30420634
Aliment Pharmacol Ther. 2016 Oct;44(8):807-16
pubmed: 27534519
Inflamm Bowel Dis. 2020 Jun 18;26(7):1079-1086
pubmed: 31587035
Gut. 2017 Apr;66(4):588-596
pubmed: 26646934
Dis Colon Rectum. 1994 Nov;37(11):1126-9
pubmed: 7956581
Clin Gastroenterol Hepatol. 2020 Jan;18(1):14-23
pubmed: 31301452
Aliment Pharmacol Ther. 2004 Mar 1;19(5):529-35
pubmed: 14987321
Am J Gastroenterol. 2018 Sep;113(9):1329-1338
pubmed: 29523864
Int J Colorectal Dis. 2018 Nov;33(11):1601-1606
pubmed: 29959529
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):847-55
pubmed: 23446333
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):338-344
pubmed: 27902515
Colorectal Dis. 2012 Mar;14(3):336-41
pubmed: 21689322
Int J Colorectal Dis. 2004 May;19(3):215-8
pubmed: 14564464
Inflamm Bowel Dis. 2017 Jul;23(7):1218-1224
pubmed: 28426474
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1583-1591.e4
pubmed: 32585362
JAMA Otolaryngol Head Neck Surg. 2017 Sep 1;143(9):899-907
pubmed: 28662244
Mayo Clin Proc. 1994 May;69(5):409-15
pubmed: 8170189
Aliment Pharmacol Ther. 2019 Mar;49(5):564-571
pubmed: 30663075
Clin Gastroenterol Hepatol. 2014 May;12(5):831-837.e2
pubmed: 24075890
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174